Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN MICHAEL HUMENIUK

Allopathic & Osteopathic Physicians Dermatology Procedural Dermatology

NPI
1639164528
CMS profile
164457
Location
GREER, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$25,604.12

117 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 3; records 1–50 of 117 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN MICHAEL HUMENIUK

NPI 1639164528 · CMS profile ID 164457

Allopathic & Osteopathic Physicians / Dermatology / Procedural Dermatology

GREER, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 3; records 1–50 of 117 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1639164528?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN MICHAEL HUMENIUK, NPI 1639164528, CMS profile ID 164457. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 117 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1639164528?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JOHN MICHAEL HUMENIUK, NPI 1639164528, CMS profile ID 164457. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 3; records 1–50 of 117 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1639164528?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JOHN MICHAEL HUMENIUK, NPI 1639164528, CMS profile ID 164457, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 3; records 1–50 of 117 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1639164528?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

117 matching records · $25,604.12 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 117 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 117.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie, Inc. $2,800.0012/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648067859 CMS
Lilly USA, LLC $18.8612/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657905183 CMS
AbbVie, Inc. $849.0612/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648067861 CMS
AbbVie, Inc. $85.0912/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648067865 CMS
AbbVie, Inc. $16.0612/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648067793 CMS
AbbVie, Inc. $4.2212/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648067863 CMS
Janssen Biotech, Inc. $10.4812/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658491885 CMS
PFIZER INC. $14.5712/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673731419 CMS
Celgene Corporation $18.4111/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672939019 CMS
AbbVie, Inc. $2,000.0011/18/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648067855 CMS
UCB, Inc. $32.1811/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688323129 CMS
AbbVie, Inc. $120.7711/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648067857 CMS
Ortho Dermatologics, a division of Bausch Health US, LLC $16.0411/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684584289 CMS
Janssen Biotech, Inc. $22.6311/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658491883 CMS
AbbVie, Inc. $15.3911/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648067791 CMS
PFIZER INC. $14.5711/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673661089 CMS
UCB, Inc. $18.9210/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688325355 CMS
Novartis Pharmaceuticals Corporation $600.0010/25/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659626721 CMS
Lilly USA, LLC $17.4510/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657918797 CMS
Celgene Corporation $20.2110/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672924251 CMS
PFIZER INC. $3.2110/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673184447 CMS
Janssen Biotech, Inc. $17.5410/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658491879 CMS
AbbVie, Inc. $21.7410/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648067841 CMS
Janssen Biotech, Inc. $0.9010/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658491875 CMS
Lilly USA, LLC $3.7610/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657922255 CMS
Novartis Pharmaceuticals Corporation $490.0009/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659626713 CMS
AbbVie, Inc. $43.5009/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648067837 CMS
AbbVie, Inc. $2,000.0009/23/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648067835 CMS
Celgene Corporation $17.9709/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672916827 CMS
AbbVie, Inc. $71.2809/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648067839 CMS
GENZYME CORPORATION $14.7709/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694164005 CMS
PFIZER INC. $13.6209/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672817729 CMS
AbbVie, Inc. $19.2609/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648067853 CMS
Novartis Pharmaceuticals Corporation $1,500.0009/10/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659626715 CMS
AbbVie, Inc. $20.6109/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648067789 CMS
Janssen Biotech, Inc. $2.3009/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658491871 CMS
Novartis Pharmaceuticals Corporation $1,500.0008/29/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659626711 CMS
UCB, Inc. $19.2308/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688306801 CMS
UCB, Inc. $7.6108/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688298307 CMS
UCB, Inc. $6.4008/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688298305 CMS
Janssen Biotech, Inc. $13.8408/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658491865 CMS
Janssen Biotech, Inc. $0.7808/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658491869 CMS
AbbVie, Inc. $9.4008/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648067801 CMS
Novartis Pharmaceuticals Corporation $16.5108/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659626709 CMS
Janssen Biotech, Inc. $14.4908/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658491858 CMS
Janssen Biotech, Inc. $4.2408/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658491861 CMS
PFIZER INC. $3.9807/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672329889 CMS
AbbVie, Inc. $2,000.0007/29/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648067847 CMS
Celgene Corporation $20.1307/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672849363 CMS
Janssen Biotech, Inc. $0.4307/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658491855 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $25,604.12 117
PY2020 $2,895.44 65
PY2021 $4,732.54 94
PY2022 $1,979.67 121
PY2023 $2,624.08 110
PY2024 $2,124.43 89
PY2025 $1,626.42 82

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,779.18 1
PY2024 Principal investigator $1,014.39 1
PY2021 Principal investigator $20,911.87 7
PY2020 Principal investigator $203,548.79 150
PY2019 Principal investigator $201,051.33 169

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

150 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AbbVie Inc. $75.00 12/01/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
M15-997 No dispute reported 06/30/2026 721198167
Principal investigator 1 Incyte Corporation $700.00 11/16/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314739
Principal investigator 1 Incyte Corporation $50.00 11/16/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314741
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 11/05/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 724478511
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $94,351.58 11/03/2020 Non-covered Recipient Entity
Clinical Research Advantage, Incorporated
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 736759381
Principal investigator 1 AbbVie Inc. $300.00 10/16/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
M15-997 No dispute reported 06/30/2026 721191221
Principal investigator 1 Incyte Corporation $1,026.00 09/07/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314713
Principal investigator 1 Incyte Corporation $700.00 09/07/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314715
Principal investigator 1 Incyte Corporation $50.00 09/07/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314717
Principal investigator 1 Incyte Corporation $50.00 09/07/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314719
Principal investigator 1 Incyte Corporation $787.00 08/14/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314645
Principal investigator 1 Incyte Corporation $789.00 08/14/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314647
Principal investigator 1 Incyte Corporation $1,026.00 08/14/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314649
Principal investigator 1 Incyte Corporation $700.00 08/14/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314651
Principal investigator 1 Incyte Corporation $939.00 08/14/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314653
Principal investigator 1 Incyte Corporation $50.00 08/14/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314655
Principal investigator 1 Incyte Corporation $787.00 08/14/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314659
Principal investigator 1 Incyte Corporation $787.00 08/14/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314661
Principal investigator 1 Incyte Corporation $700.00 08/14/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314663
Principal investigator 1 Incyte Corporation $50.00 08/14/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314665
Principal investigator 1 Incyte Corporation $50.00 08/14/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314667
Principal investigator 1 Incyte Corporation $50.00 08/14/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314669
Principal investigator 1 Incyte Corporation $50.00 08/14/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314671
Principal investigator 1 Incyte Corporation $50.00 08/14/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314673
Principal investigator 1 Incyte Corporation $50.00 08/14/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314675
Principal investigator 1 Incyte Corporation $50.00 08/14/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314721
Principal investigator 1 Incyte Corporation $789.00 08/07/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314639
Principal investigator 1 Incyte Corporation $700.00 08/07/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314641
Principal investigator 1 Incyte Corporation $50.00 08/07/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314643
Principal investigator 1 Incyte Corporation $50.00 08/07/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314657
Principal investigator 1 AbbVie Inc. $1,801.00 07/30/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
M15-997 No dispute reported 06/30/2026 721177845
Principal investigator 1 AbbVie Inc. $128.00 07/29/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
M15-997 No dispute reported 06/30/2026 721177113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,898.95 07/28/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF DUPILUMAB IN PATIENTS >=6 MONTHS TO <18 YEARS OF AGE WITH ATOPIC DERMATITIS No dispute reported 06/30/2026 724471859
Principal investigator 1 Incyte Corporation $786.00 06/05/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314563
Principal investigator 1 Incyte Corporation $787.00 06/05/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314565
Principal investigator 1 Incyte Corporation $789.00 06/05/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314567
Principal investigator 1 Incyte Corporation $1,026.00 06/05/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314569
Principal investigator 1 Incyte Corporation $50.00 06/05/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314571
Principal investigator 1 Incyte Corporation $787.00 06/05/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314621
Principal investigator 1 Incyte Corporation $789.00 06/05/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314623
Principal investigator 1 Incyte Corporation $1,026.00 06/05/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314625
Principal investigator 1 Incyte Corporation $50.00 06/05/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314627
Principal investigator 1 Incyte Corporation $50.00 06/05/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314629
Principal investigator 1 Incyte Corporation $50.00 06/05/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314631
Principal investigator 1 Incyte Corporation $50.00 06/05/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314633
Principal investigator 1 Incyte Corporation $50.00 06/05/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314635
Principal investigator 1 Incyte Corporation $50.00 06/05/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314637
Principal investigator 1 Incyte Corporation $786.00 05/18/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314553
Principal investigator 1 Incyte Corporation $787.00 05/18/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314555
Principal investigator 1 Incyte Corporation $789.00 05/18/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314557
Principal investigator 1 Incyte Corporation $700.00 05/18/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314559
Principal investigator 1 Incyte Corporation $50.00 05/18/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314561
Principal investigator 1 Incyte Corporation $786.00 05/18/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314599
Principal investigator 1 Incyte Corporation $787.00 05/18/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314601
Principal investigator 1 Incyte Corporation $789.00 05/18/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314603
Principal investigator 1 Incyte Corporation $789.00 05/18/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314605
Principal investigator 1 Incyte Corporation $50.00 05/18/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314607
Principal investigator 1 Incyte Corporation $50.00 05/18/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314609
Principal investigator 1 Incyte Corporation $50.00 05/18/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314611
Principal investigator 1 Incyte Corporation $50.00 05/18/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314613
Principal investigator 1 Incyte Corporation $50.00 05/18/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314615
Principal investigator 1 Incyte Corporation $50.00 05/18/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314617
Principal investigator 1 Incyte Corporation $50.00 05/18/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314619
Principal investigator 1 AbbVie Inc. $1,421.00 04/30/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
M15-997 No dispute reported 06/30/2026 721163625
Principal investigator 1 AbbVie Inc. $75.00 04/29/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
M15-997 No dispute reported 06/30/2026 721162711
Principal investigator 1 UCB SA $34.00 04/09/2020 Non-covered Recipient Entity
RADIANT RESEARCH
A MULTICENTER, OPEN-LABEL STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS No dispute reported 06/30/2026 753372929
Principal investigator 1 Incyte Corporation $856.00 04/08/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314543
Principal investigator 1 Incyte Corporation $786.00 04/08/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314545
Principal investigator 1 Incyte Corporation $787.00 04/08/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314547
Principal investigator 1 Incyte Corporation $789.00 04/08/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314549
Principal investigator 1 Incyte Corporation $50.00 04/08/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314551
Principal investigator 1 Incyte Corporation $786.00 04/08/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314573
Principal investigator 1 Incyte Corporation $786.00 04/08/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314575
Principal investigator 1 Incyte Corporation $786.00 04/08/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314577
Principal investigator 1 Incyte Corporation $787.00 04/08/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314579
Principal investigator 1 Incyte Corporation $789.00 04/08/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314581
Principal investigator 1 Incyte Corporation $50.00 04/08/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314583
Principal investigator 1 Incyte Corporation $50.00 04/08/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314585
Principal investigator 1 Incyte Corporation $50.00 04/08/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314587
Principal investigator 1 Incyte Corporation $50.00 04/08/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314589
Principal investigator 1 Incyte Corporation $50.00 04/08/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314591
Principal investigator 1 Incyte Corporation $50.00 04/08/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314593
Principal investigator 1 Incyte Corporation $50.00 04/08/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314595
Principal investigator 1 Incyte Corporation $50.00 04/08/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314597
Principal investigator 1 Incyte Corporation $997.00 03/23/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314477
Principal investigator 1 Incyte Corporation $1,079.00 03/23/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314479
Principal investigator 1 Incyte Corporation $991.00 03/23/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314481
Principal investigator 1 Incyte Corporation $992.00 03/23/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314483
Principal investigator 1 Incyte Corporation $50.00 03/23/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314485
Principal investigator 1 Incyte Corporation $1,079.00 03/23/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314521
Principal investigator 1 Incyte Corporation $992.00 03/23/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314523
Principal investigator 1 Incyte Corporation $992.00 03/23/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314525
Principal investigator 1 Incyte Corporation $992.00 03/23/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314527
Principal investigator 1 Incyte Corporation $50.00 03/23/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314529
Principal investigator 1 Incyte Corporation $50.00 03/23/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314531
Principal investigator 1 Incyte Corporation $50.00 03/23/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314533
Principal investigator 1 Incyte Corporation $50.00 03/23/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314535
Principal investigator 1 Incyte Corporation $50.00 03/23/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314537
Principal investigator 1 Incyte Corporation $50.00 03/23/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314539
Principal investigator 1 Incyte Corporation $50.00 03/23/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314541
Principal investigator 1 Incyte Corporation $995.00 02/12/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314391
Principal investigator 1 Incyte Corporation $997.00 02/12/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314393
Principal investigator 1 Incyte Corporation $1,079.00 02/12/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314395
Principal investigator 1 Incyte Corporation $991.00 02/12/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314397
Principal investigator 1 Incyte Corporation $992.00 02/12/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314399
Principal investigator 1 Incyte Corporation $50.00 02/12/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314401
Principal investigator 1 Incyte Corporation $995.00 02/12/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314431
Principal investigator 1 Incyte Corporation $995.00 02/12/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314433
Principal investigator 1 Incyte Corporation $997.00 02/12/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314435
Principal investigator 1 Incyte Corporation $997.00 02/12/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314487
Principal investigator 1 Incyte Corporation $991.00 02/12/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314489
Principal investigator 1 Incyte Corporation $991.00 02/12/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314491
Principal investigator 1 Incyte Corporation $991.00 02/12/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314493
Principal investigator 1 Incyte Corporation $992.00 02/12/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314495
Principal investigator 1 Incyte Corporation $50.00 02/12/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314497
Principal investigator 1 Incyte Corporation $50.00 02/12/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314499
Principal investigator 1 Incyte Corporation $50.00 02/12/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314501
Principal investigator 1 Incyte Corporation $50.00 02/12/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314503
Principal investigator 1 Incyte Corporation $50.00 02/12/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314505
Principal investigator 1 Incyte Corporation $50.00 02/12/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314507
Principal investigator 1 Incyte Corporation $50.00 02/12/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314509
Principal investigator 1 Incyte Corporation $50.00 02/12/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314511
Principal investigator 1 Incyte Corporation $50.00 02/12/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314513
Principal investigator 1 Incyte Corporation $50.00 02/12/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314515
Principal investigator 1 Incyte Corporation $50.00 02/12/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314517
Principal investigator 1 Incyte Corporation $50.00 02/12/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314519
Principal investigator 1 AbbVie Inc. $75.00 02/05/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
M15-997 No dispute reported 06/30/2026 721149637
Principal investigator 1 AbbVie Inc. $1,093.50 01/30/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC
M15-997 No dispute reported 06/30/2026 721148065
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $33,795.75 01/07/2020 Non-covered Recipient Entity
Clinical Research Advantage, Incorporated
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study with an Induction Period Followed by a Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 in Subjects with Mod No dispute reported 06/30/2026 736759385
Principal investigator 1 Incyte Corporation $46.00 01/06/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314379
Principal investigator 1 Incyte Corporation $1,076.00 01/06/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314381
Principal investigator 1 Incyte Corporation $995.00 01/06/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314383
Principal investigator 1 Incyte Corporation $997.00 01/06/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314385
Principal investigator 1 Incyte Corporation $991.00 01/06/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314387
Principal investigator 1 Incyte Corporation $50.00 01/06/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314389
Principal investigator 1 Incyte Corporation $46.00 01/06/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314403
Principal investigator 1 Incyte Corporation $46.00 01/06/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314405
Principal investigator 1 Incyte Corporation $46.00 01/06/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314407
Principal investigator 1 Incyte Corporation $46.00 01/06/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314409
Principal investigator 1 Incyte Corporation $46.00 01/06/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314411
Principal investigator 1 Incyte Corporation $1,076.00 01/06/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314413
Principal investigator 1 Incyte Corporation $991.00 01/06/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314415
Principal investigator 1 Incyte Corporation $991.00 01/06/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314417
Principal investigator 1 Incyte Corporation $50.00 01/06/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314419
Principal investigator 1 Incyte Corporation $50.00 01/06/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314421
Principal investigator 1 Incyte Corporation $50.00 01/06/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314423
Principal investigator 1 Incyte Corporation $50.00 01/06/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314425
Principal investigator 1 Incyte Corporation $50.00 01/06/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314427
Principal investigator 1 Incyte Corporation $50.00 01/06/2020 Non-covered Recipient Entity
SYNEXUS CLINICAL RESEARCH US INC. GREER
TRuE AD1-An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis No dispute reported 06/30/2026 744314429
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,955.01 01/01/2020 Non-covered Recipient Entity
RADIANT RESEARCH
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP DOSE RANGING STUDY TO DETERMINE THE EFFICACY AND SAFETY OF ORAL ZPL389A 3 MG 10 MG 30 MG AND 50 MG CAPSULES ADMINISTERED FOR 16 WEEKS IN SUBJECTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 721494813